Vanda Pharmaceuticals Inc. VNDA
We take great care to ensure that the data presented and summarized in this overview for Vanda Pharmaceuticals Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VNDA
View all-
Black Rock Inc. New York, NY8.14MShares$40 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny4.01MShares$19.7 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.63MShares$17.9 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.35MShares$11.6 Million0.94% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.26MShares$11.1 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.9MShares$9.35 Million0.03% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT1.59MShares$7.84 Million0.44% of portfolio
-
Pictet Asset Management Sa Geneva 73, V81.57MShares$7.7 Million0.01% of portfolio
-
Jacobs Levy Equity Management, Inc Florham Park, NJ1.43MShares$7.04 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA1.43MShares$7.02 Million0.0% of portfolio
Latest Institutional Activity in VNDA
Top Purchases
Top Sells
About VNDA
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Insider Transactions at VNDA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 14
2024
|
Stephen Ray Mitchell |
SELL
Open market or private sale
|
Direct |
5,000
-10.03%
|
$25,000
$5.17 P/Share
|
Jul 29
2024
|
Kevin Patrick Moran SVP, CFO & Treasurer |
SELL
Open market or private sale
|
Direct |
2,251
-0.97%
|
$11,255
$5.92 P/Share
|
May 22
2024
|
Phaedra Chrousos |
BUY
Grant, award, or other acquisition
|
Direct |
21,887
+25.45%
|
-
|
May 17
2024
|
Tage Honore |
BUY
Grant, award, or other acquisition
|
Direct |
20,529
+24.22%
|
-
|
May 17
2024
|
Anne Sempowski Ward |
BUY
Grant, award, or other acquisition
|
Direct |
20,529
+25.54%
|
-
|
May 17
2024
|
Stephen Ray Mitchell |
BUY
Grant, award, or other acquisition
|
Direct |
20,529
+29.17%
|
-
|
May 17
2024
|
Richard W Dugan |
BUY
Grant, award, or other acquisition
|
Direct |
20,529
+14.79%
|
-
|
Mar 05
2024
|
Timothy Williams SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
8,941
-4.35%
|
$35,764
$4.18 P/Share
|
Mar 05
2024
|
Gunther Birznieks SVP, Business Development |
SELL
Open market or private sale
|
Direct |
8,684
-2.69%
|
$34,736
$4.13 P/Share
|
Mar 05
2024
|
Kevin Patrick Moran SVP, CFO & Treasurer |
SELL
Open market or private sale
|
Direct |
8,902
-3.71%
|
$35,608
$4.2 P/Share
|
Mar 05
2024
|
Mihael Hristos Polymeropoulos President and CEO |
SELL
Open market or private sale
|
Direct |
24,288
-1.28%
|
$97,152
$4.13 P/Share
|
Mar 05
2024
|
Joakim Wijkstrom SVP, Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
9,229
-6.64%
|
$36,916
$4.21 P/Share
|
Mar 04
2024
|
Timothy Williams SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
8,147
-3.81%
|
$32,588
$4.41 P/Share
|
Mar 04
2024
|
Gunther Birznieks SVP, Business Development |
SELL
Open market or private sale
|
Direct |
8,727
-2.64%
|
$34,908
$4.3 P/Share
|
Mar 04
2024
|
Kevin Patrick Moran SVP, CFO & Treasurer |
SELL
Open market or private sale
|
Direct |
5,798
-2.36%
|
$23,192
$4.48 P/Share
|
Mar 04
2024
|
Mihael Hristos Polymeropoulos President and CEO |
SELL
Open market or private sale
|
Direct |
30,884
-1.6%
|
$123,536
$4.24 P/Share
|
Mar 04
2024
|
Joakim Wijkstrom SVP, Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
7,498
-5.12%
|
$29,992
$4.41 P/Share
|
Feb 16
2024
|
Timothy Williams SVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+36.88%
|
-
|
Feb 16
2024
|
Gunther Birznieks SVP, Business Development |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+27.41%
|
-
|
Feb 16
2024
|
Mihael Hristos Polymeropoulos President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
450,000
+18.93%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 962K shares |
---|
Open market or private sale | 128K shares |
---|